BVS857
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercatabolic Status Related to Severe Burn
Conditions
Hypercatabolic Status Related to Severe Burn
Trial Timeline
Feb 1, 2014 → Jan 1, 2015
NCT ID
NCT02074995About BVS857
BVS857 is a phase 2 stage product being developed by Novartis for Hypercatabolic Status Related to Severe Burn. The current trial status is terminated. This product is registered under clinical trial identifier NCT02074995. Target conditions include Hypercatabolic Status Related to Severe Burn.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02074995 | Phase 2 | Terminated |